What is disclosed is a protein supplement drink mix comprising at least one base protein and a plurality of second components, each second component having at least one different active ingredient pre-selected for the physiological needs regarding a pre-determined activity, age, and/or gender demographic. The first component and the second component are mixed generally with a liquid to provide a base for a protein drink, although a liquid can form a portion of the first component or second components.

What is disclosed is a protein supplement drink mix comprising at least one base protein and a plurality of second components, each second component having at least one different active ingredient pre-selected for the physiological needs regarding a pre-determined activity, age, and/or gender demographic. The first component and the second component are mixed generally with a liquid to provide a base for a protein drink, although a liquid can form a portion of the first component or second components.

The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1.

The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1.

The present invention generally relates to the field of medical nutrition. For example, the present invention provides a composition that can be used to treat, prevent and/or reverse muscle atrophy related to immobilization and its consequences. One embodiment of the present invention concerns a composition comprising a leucine and antioxidants that can be used in accelerating muscle recovery after muscle atrophy.

The present invention relates to an amino acid composition comprising threonine, serine, proline, leucine, and cysteine for use in preventing and/or reducing glutamine deficiency and/or arginine deficiency in a subject. The present invention also relates to an enteral nutritional composition comprising threonine, serine, proline, leucine, and cysteine and a method for producing the same.

The present invention relates to an amino acid composition comprising threonine, serine, proline, leucine, and cysteine for use in preventing and/or reducing glutamine deficiency and/or arginine deficiency in a subject. The present invention also relates to an enteral nutritional composition comprising threonine, serine, proline, leucine, and cysteine and a method for producing the same.

The present invention relates to an amino acid composition comprising threonine, serine, proline, leucine, and cysteine for use in improving liver function in a subject. The present invention also relates to an enteral nutritional composition comprising threonine, serine, proline, leucine, and cysteine and a method for producing the same.

The present invention relates to an amino acid composition comprising threonine, serine, proline, leucine, and cysteine for use in improving liver function in a subject. The present invention also relates to an enteral nutritional composition comprising threonine, serine, proline, leucine, and cysteine and a method for producing the same.

The invention provides a food supplement comprising chromium and the five amino acids leucine, isoleucine, valine, threonine and lysine, wherein leucine, isoleucine, valine, threonine and lysine are the only amino acids present in the food supplement, and wherein the sum content of the five amino acids is from 1.75 to 3.5 g per dose of the food supplement, and wherein the content of chromium is from 4.5 to 61 g per dose of the food supplement. A food composition comprising the food supplement, as well as the five amino acids for use in a method of treating, controlling or preventing diseases or conditions related to the metabolic syndrome, treating or controlling diabetes, treating, controlling or preventing obesity, promoting satiety, promoting weight loss, or promoting maintenance of a healthy bodyweight, by lowering postprandial glycaemia, and preferably also by lowering postprandial insulin secretion, are also provided.